Global Antifibrinolytic Drugs Market In the Rise and May Reach USD 21.2 Billion By 2028

In 2022, the worldwide antifibrinolytic medicines market is expected to be worth US$ 16.2 billion. In the future, it is predicted to rise to US$ 21.2 billion by 2028, with a compound annual growth rate (CAGR) of 4.5% from 2023 to 2028. Antifibrinolytic drugs are pharmaceuticals that promote the production of blood clots in order to avoid fibrinolysis or obstruction in arteries and veins.

These medications suppress the activation of plasminogen, preventing fibrin lysis and maintaining clot stability. They are used to treat hemorrhages, vascular tumors, and to relieve severe menstrual bleeding. They are also used to reduce bleeding during or after invasive surgical procedures. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors.

They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers, as per Research and Markets. Antifibrinolytic medications are critical for preventing clot lysis and reducing blood loss.

In accordance with this, rising health consciousness and awareness among the general public about the available treatment options for hereditary angioedema and hemophilia are also helping to market growth. Other growth-inducing variables include technical improvements and the increased use of antifibrinolytic treatment to minimize transfusion in orthopedic patients. Pharmaceutical companies are also working on novel oral and intravenous medication variations with improved efficacy and bioabsorbability.